AI Article Synopsis
- A 60-year-old man experienced numbness and weakness in his right arm, leading to the discovery of a mass in his right lung that was diagnosed as primary lung adenocarcinoma.
- The cancer was staged as IIIA and positive for programmed death ligand 1, but negative for certain genetic mutations; he was treated with neoadjuvant tislelizumab and chemotherapy.
- Post-treatment, the patient showed significant tumor shrinkage (71%) and achieved a complete pathological response, with no circulating tumor cells detected after the first round of adjuvant therapy.
Article Abstract
A 60-year-old man was hospitalized because of numbness and weakness in the right upper limb. Magnetic resonance imaging revealed a large mass in the right upper lobe invading the right eighth cervical and first thoracic nerve root. Biopsy pathology confirmed primary lung adenocarcinoma with a clinical stage of cT4N0M0 IIIA, negative for anaplastic lymphoma kinase fusion gene and epidermal growth factor receptor mutations but positive for programmed death ligand 1 (3%). Neoadjuvant tislelizumab and chemotherapy were offered to this patient with Pancoast tumor, and tumor shrinkage of 71% was achieved. After the operation, surgical pathology indicated pathologic complete response (pCR). Circulating tumor cells testing was negative after the first adjuvant treatment. In this case, we provide real-world evidence of encouraging pCR with neoadjuvant tislelizumab and chemotherapy for a patient with Pancoast tumor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046127 | PMC |
| http://dx.doi.org/10.1111/1759-7714.13910 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!